Hardman Johnston Global Advisors LLC reduced its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 252,220 shares of the pharmaceutical company’s stock after selling 3,930 shares during the period. Vertex Pharmaceuticals makes up about 2.1% of Hardman Johnston Global Advisors LLC’s investment portfolio, making the stock its 13th largest position. Hardman Johnston Global Advisors LLC owned about 0.10% of Vertex Pharmaceuticals worth $48,613,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mount Yale Investment Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $101,000. Kaizen Advisory LLC increased its position in shares of Vertex Pharmaceuticals by 147.3% during the second quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after purchasing an additional 358 shares during the period. Sun Life Financial INC increased its position in shares of Vertex Pharmaceuticals by 266.1% during the second quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock valued at $118,000 after purchasing an additional 503 shares during the period. Flagship Harbor Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Vertex Pharmaceuticals by 3,126.1% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock valued at $126,000 after purchasing an additional 719 shares during the period. 93.47% of the stock is currently owned by institutional investors.

Shares of VRTX stock opened at $185.48 on Thursday. The company has a current ratio of 3.67, a quick ratio of 3.55 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $49.26 billion, a P/E ratio of 231.85, a P/E/G ratio of 1.96 and a beta of 1.48. Vertex Pharmaceuticals Incorporated has a one year low of $136.50 and a one year high of $194.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.54. The business had revenue of $752.20 million for the quarter, compared to analyst estimates of $680.86 million. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. Vertex Pharmaceuticals’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.39 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 2.48 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on the company. BMO Capital Markets boosted their price objective on Vertex Pharmaceuticals to $204.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Oppenheimer boosted their price objective on Vertex Pharmaceuticals from $180.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Jefferies Financial Group boosted their price objective on Vertex Pharmaceuticals to $210.00 and gave the company a “buy” rating in a research report on Monday, July 16th. UBS Group boosted their price objective on Vertex Pharmaceuticals from $183.00 to $188.00 and gave the company a “neutral” rating in a research report on Thursday, July 26th. Finally, Morgan Stanley boosted their price objective on Vertex Pharmaceuticals from $207.00 to $211.00 and gave the company an “overweight” rating in a research report on Thursday, July 26th. Four analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $197.68.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 2,098 shares of the business’s stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $174.44, for a total value of $365,975.12. Following the transaction, the senior vice president now owns 17,376 shares of the company’s stock, valued at $3,031,069.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP David Altshuler sold 2,445 shares of the business’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $194.62, for a total value of $475,845.90. The disclosure for this sale can be found here. In the last three months, insiders sold 33,325 shares of company stock worth $6,135,340. Insiders own 0.75% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

See Also: How Do You Make Money With Penny Stocks?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.